🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
6.90
-0.41 (-5.61%)
At close: Nov 20, 2026, 4:00 PM EST
6.99
+0.09 (1.25%)
After-hours: Nov 20, 2026, 7:59 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

AMTAGVI and PROLEUKIN revenue reached $122M in Q3, with FY 2026 guidance of $410M–$420M. Development plans include a 2027 lung sBLA, first-line melanoma work and expanding sarcoma trials.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I'm gonna get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today, and it's my pleasure to have the Iovance team. To my direct right, Corleen Roche, CFO, and to her right, Dan Kirby, Chief Commercial Officer. To Dan's right is Brian Gastman, I guess, Executive VP Translational Medicine. Is that the right—

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Right, correct.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. To the right of Brian is Noah Berkowitz, Chief Medical Officer. Welcome, all of you. Maybe just to get started, you've launched a novel TIL therapy, AMTAGVI. It's almost been three years since the initial approval in February of 2024. Maybe talk us through where are we in the launch right now, and looking ahead, you're broadening the pipeline with this product. What catalysts can we look forward to over the next 12 months? That would be helpful.

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Absolutely. Thank you, Andrew, and thanks for having us. If we look at where we just finished the third quarter, we did about $122 million in sales in the U.S. for AMTAGVI and PROLEUKIN. In context, we did $264 million all of 2025. When you think about that, the growth has been very strong, especially this year with AMTAGVI. It's a one-time cell therapy in solid tumor, and we've been able to establish a platform of not only treatment centers and surgical oncologists, but also medical oncologists referring those in, that is sustainable and continues to grow. If you look at where we're excited about going forward is opening more ATCs, seeing that growth continue through Q4 into 2027 and beyond. Our focus is to maximize the opportunity in melanoma in the U.S., second- line plus metastatic melanoma, getting more approvals.

We're approved right now in the U.S., Canada, and Australia. We have approvals pending in Switzerland and the U.K., and we're engaging with the European Union on resubmission. Again, we see an ex-U.S. market being very viable in the melanoma space. We have studies going on in frontline melanoma, which would about triple our potential in that space. Then, of course, everything for 2027, building off melanoma, does apply with the platform going into lung.

We've released some data on lung recently, but also are preparing to file next year and enter the market in second- line plus lung cancer, and that really is a huge opportunity for us. Also, I want to mention sarcoma trials are ongoing. We've released data recently on sarcoma, and we see opportunities there as well. But again, the platform has been built, and we're growing it, so a lot of good things are happening.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. So yeah, you're scaling. The total addressable market in second-line melanoma, can you remind us how many patients that is per year? You just mentioned first- line would be 3x. How about lung? How big is it compared to second-line melanoma?

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Sure. If we look at it right now in the U.S. alone, second- line plus metastatic melanoma, about 8,500 patients. We go 22,000 + when we get into first- line. If we look at the opportunities in other indications, in lung, we released data on non-squamous, and if we look at that market in non-squamous lung is 7x what we see the market potential in melanoma. If we look at actually the data showing KRAS wild-type, we saw biomarkers for KRAS wild-type, HER2-positive, ever smokers.

That subset, where we saw about 60% efficacy in that patient population in the data released, that is 3x what we see in the melanoma market in second- line plus. If we look at all of non-squamous at 7x, if we look at frontline plus second- line, in KRAS wild-type is about 10 x. It's a multi-billion dollar opportunity no matter how you look at it, and that's U.S. numbers. You can expand that as you look ex-U.S.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Before I forget, the sarcoma indications, the rare sarcomas, how big is that?

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

That opportunity there, because there really is nothing for those patients with it, that opportunity is equal to second-line plus metastatic melanoma.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Around 8,500 kind of thing. You mentioned 80—

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Well, the patient population's lower, but the penetration's greater.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Oh, I see.

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Yes.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Understood. Going back to AMTAGVI for second-line melanoma, which is launching right now, you mentioned one of the priorities is these ATC sites, increasing. Anything else you are focused on to drive more growth?

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Absolutely. Since I got here in February 2025, that is really where we started to see more and more penetration in the market with it, there has been three key areas of focus. The first one is looking at physician awareness. We have been able to raise, and I have talked about the very high numbers in treater awareness, but also too, we are focused on increasing referrer awareness. We see that growing in the surveys that we are having all the time and the efforts we are doing in the community space to get patients referred in earlier. That is the first area of focus. We talked about the ATCs, our authorized treatment centers for AMTAGVI.

We continue to grow those. We had said we would open at least 110 by the end of the year, as we talked about in our earnings call a few weeks ago. We are well on track for that. We are on track to meet or exceed that goal. We will continue to expand our ATCs, and what that does, it brings the product closer to the patients for it and gets within the referral networks there. The third area of focus is clinical data. As you have seen over the last year, we have released some very impressive data on second-line plus metastatic melanoma, showing that in the second-line treatment, two or fewer lines, over half the patients are having a response.

We also released five-year data that showed that 36+ months was our overall median duration of survival. That, in this setting, is unheard of, and that is where we are seeing physicians respond really well. We are focused on releasing more of that data as we move forward.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect. As I think about your Q4 sales, I mean, you've guided 2026 to, I believe, $410 million-$420 million. You did $118 million in Q3, so year to date, it's around $290 million for the year. If I kind of backed it out, Q4 would imply like $118 million and $128 million, like a flattish to up slightly growth. Slightly up type of growth. We're 1.5 months into Q4. How do you feel, Corleen, about Q4?

Corleen Roche
CFO, Iovance Biotherapeutics

Yeah, absolutely. Let me take that. Can you hear me? Hi, everyone. Thanks for coming. It's a little tight in here. In Q3, we had our highest revenue quarter ever, $122 million.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Oh.

Corleen Roche
CFO, Iovance Biotherapeutics

Right? Year to date, we're at $292 million, and that compares to a full- year last year of $264 million. We were very, very happy to raise our guidance to $410 million to $420 million, which shows growth that we continue to see. I think we're in really good shape.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. You feel good about—

Corleen Roche
CFO, Iovance Biotherapeutics

We feel good. Yep.

Andrew Tsai
Senior Biotech Analyst, Jefferies

All right, good. And so, come that January in JPMorgan. Will we expect an update with you? Are you the type to pre-announce?

Corleen Roche
CFO, Iovance Biotherapeutics

We have not typically pre-announced. However, I will continue to think about that. What I can tell you is that you've seen what we can do, and we're going to continue to treat as many patients as we possibly can, so expect growth.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Can we expect you around that time, if not then Q4 EPS, to provide 2027 guidance or even Q1 2027 guidance?

Corleen Roche
CFO, Iovance Biotherapeutics

We are continuing to think about what the right timing is for that, yes.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, great. So come Q1, I think, as I reflect over the past few years of your launches, there has been kind of a maintenance period, one to two weeks long, in parts of late Q4, I believe, then maybe early Q1. Will we expect that kind of maintenance disruption to your manufacturing site going forward?

Corleen Roche
CFO, Iovance Biotherapeutics

The answer is no, the short answer. Basically, you always have to do maintenance on the plant. However, the last time we took a pause to do some maintenance, we upgraded the facility so that that maintenance will not disrupt the production. So you will not see it, basically.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. Thanks. So now sales are growing, like you are saying. Gross margins are also expanding. How confident are you that it will continue to improve in 2027 on a quarterly basis? Is there choppiness?

Corleen Roche
CFO, Iovance Biotherapeutics

So look, there could be. I will just reiterate, remember that we again had our highest margin quarter ever in Q3, and that was 60%, which brings our year-to-date margin to 54%. That is built on fundamentals. It is cost control, it is operational efficiencies. We are consistently targeting process improvements, et cetera, everything in the plant that can make things more efficient so we can make more product with the same resources. So I would say it will continue. Can I guarantee a certain amount of quarter-over-quarter? No, just not how it works. But over the long term, we will see that.

Andrew Tsai
Senior Biotech Analyst, Jefferies

And the long-term goal has been 70% or above that?

Corleen Roche
CFO, Iovance Biotherapeutics

Yes. I haven't given a timeframe, but yes, that is the goal.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. But you are already at 60%.

Corleen Roche
CFO, Iovance Biotherapeutics

We're already at 60%.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Corleen Roche
CFO, Iovance Biotherapeutics

Yes.

Andrew Tsai
Senior Biotech Analyst, Jefferies

All right. And so you joined, was it last year?

Corleen Roche
CFO, Iovance Biotherapeutics

August of 2025.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. And you've done a good job reducing the overall OpEx structure too—

Corleen Roche
CFO, Iovance Biotherapeutics

Yes.

Andrew Tsai
Senior Biotech Analyst, Jefferies

—on the OpEx side. I think maybe it is like $90 million a quarter. Could that grow actually as you are expanding the AMTAGVI pipeline, or are you kind of—

Corleen Roche
CFO, Iovance Biotherapeutics

I think that we are coming from a really strong place. Our balance sheet is strong. We had $382 million at the end of the quarter, the last quarter reported. We are running, for example, our clinical trials much more efficiently. We can scale and work towards all of these great opportunities in the pipeline while keeping financial discipline. You saw the R&D is under control. We are keeping all of the OpEx under control in addition to the cost of goods.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, perfect. As I think about 2027 sales, there is obviously the demand side, but you also took price increases in the past. Can we expect a price increase in 2027 that could help you?

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Yes. We have already announced to the ATCs and to the payers, we are taking a 9% price increase on AMTAGVI and a 7% on PROLEUKIN effective January 1st.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Got it. You guys mentioned earlier that you are expanding ex-U.S. Is this something you are handling yourselves? Will this, your manufacturing site be able to supply globally, or do you have other sites? Maybe talk us through the ex-U.S.

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Absolutely. We have approvals, as I mentioned, in three areas, U.S., Canada, and Australia. We have approvals pending. We are expecting in Q1 in Switzerland and U.K., and then we are looking to resubmit with European Union, working with KOLs and the EMA there. We can handle all of that in the Philadelphia facility. It is modular. As we moved on from contract manufacturing this year to solely manufacturing out of Philadelphia, we opened our second module up. We have several more modules we can open up in that facility. One thing to keep in mind, we can ship, and we do this in clinical trial anywhere in the world, over to Philadelphia, the tumor tissue, to manufacture for a one-time infusion. When we ship out of Philadelphia, it is cryo. We have a 12-month shelf life on the product for it.

Again, we can scale with our existing infrastructure without having to spend more capital, opening up new facilities. Will we open them up in the future with it as demand grows and we get the indications? Of course, that is something we will put on the table, but that is not in the immediate plans.

Andrew Tsai
Senior Biotech Analyst, Jefferies

All right. Well, good job executing this year. Moving on to the pipeline, I guess, again, you are launching a second- line, but you have a first-line study, TILVANCE-301, going on. I think it has a dual purpose. It is meant for confirmatory of the second- line, but also accelerated for the first- line. That is how I understand it. How is enrollment going? When can we expect data for that one?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

You can take it. Noah's our new CMO, rather new, and I've been doing this for a little bit, so I'll take it. Thank you, Andrew. Just to remind everybody what TILVANCE-301 is, it's a multi-center international phase III clinical trial. It actually does serve actually three purposes. The first is as a confirmatory trial to our accelerated approval in the United States. The second is to gain accelerated approval in the front line, and ultimately, as it pans out, it could be confirmatory for the front line as well. It is moving along. It is definitely well underway.

It definitely meets and probably exceeds the definition of what the FDA requires of us. We have not guided yet to when we're going to give the data, but you can expect that's something that's top of mind. Because it's a phase III trial, heavily regulated by the regulators, we are very careful when we do independent review data cuts. As soon as we make that decision, I certainly will be getting back to you on that.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. This is a combination with PD-1 versus PD-1 alone. What kind of ORR or PFS do you want to see, ideally?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Well, I think what's great is that we just presented data on our IOV-COM-202 Cohort 1A data, which really guides us to our experimental arm.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Oh, so that's your phase II first- line, to be clear.

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Exactly, right. We actually did our final data cut. We are working on the manuscript as we speak. What's really amazing with that one was that not only did we see an above 60% response rate, but the complete response rate was higher than you'll ever see. I was in clinical practice treating melanoma patients. To see such high CR rates is really unprecedented. The key isn't just the CR rates. The key is that there's actually data that if you get a CR in a TIL, 10 years later, almost 100% of patients, including from car accidents, heart attacks, were alive. It's really impressive. We think that's an extremely high mark to have versus what you would expect with PD-1 monotherapy, where whether you look at pembrolizumab or nivolumab, you're looking at around 6%-10% CR rates.

That alone, besides the much higher expected ORR rate, are reasons why we're very confident about this trial.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. Thank you. Shifting gears to lung, like Dan Kirby just said, you guys reported some updated lung data. 25% ORR on 69 patients. It was relatively unchanged relative to the first cut that you did. The DOR was not yet reached, but at this juncture, the ultimate goal, my understanding, is 80 patients, so you are very close. But ultimately, what is the median DOR you think, at a minimum, you guys can have, and how does that compare to existing therapies for second-line lung?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

It is important to note, this is the IOV-COM-202, excuse me, the IOV-LUN-202 trial, which is our registrational trial for EGFR ROS ALK wild-type population. I have been in the company, we have actually did three press releases on it, and the response rates have been basically rock steady. About one in four patients are responding. The first two that we showed, there was no duration of response reached with over The last one with over two years of follow-up. This most recent one is too immature to say yet. As my CEO said, he gave out a number, but we still do not know. It may still be not reached once this immature data actually comes in. More to come on that, but I would say it is reminiscent of what we have seen in melanoma, which we have seen incredibly long durations. Your question one more time was?

Andrew Tsai
Senior Biotech Analyst, Jefferies

On doce or chemotherapy—

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

What would that show in second- line?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Sure. The benchmark, generally speaking, is docetaxel, which is chemotherapy. It is used in all the phase III randomized controlled trials for registration. Typical response rate is around 13%. Median OS is around a year, and PFS is less than six months. Really, a lot of the DOR data is even worse than that. It is a very low benchmark, you would think, and yet many other companies have not been able to actually beat it. That being said, if you look at our swimmer's plots, we have patients with multiple years swimming along, and that really is the promise of this therapy.

I think what people don't realize is how poor the unmet need is in this population and how large this population is. I think Dan and I were on a meeting recently with the largest lung advocacy group in the world, and they were really surprised how good the data is. We are really confident that what we have here is something that is beyond what is available to patients now.

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Yeah, and one thing I will just add to that, it is a one-time therapy, and so we are on with longevity, as the patient therapy was talking about and their clinical team. Off of one infusion, you are getting durable responses. What does strike home is you don't have constant administration and constant toxicities. Looking at this patient type, you are getting the responses with one-time therapy, and that is very important, and that will change the game for these patients.

Andrew Tsai
Senior Biotech Analyst, Jefferies

In this updated data cut, can you confirm whether efficacy remained the same for patients who had I think you reduced the dose for lymphodepletion, but I am just curious, was there an efficacy differential once you changed it?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Well, the majority of the patients now are on that lower dose. It is important to also note that that dose was actually available, excuse me, to patients well before we made that change in the protocol. The protocol, actually, all it did was it gave away the other option as well. But what we have seen is basically rock-steady response rates through multiple years and multiple data cuts that we have provided publicly, and we have seen long-term swimmers from this lower dose lymphodepletion.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see.

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

But I think more important, as importantly, the safety is improving, and so that is why we have made the change.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes.

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

It bodes well for the phase III eventually.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great.

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Yeah, the short answer is no, we have not seen a difference of response or duration.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thanks. Speaking of safety, some investors wanted to see a little bit more on the AE breakdown and so forth. Can you tell us how the safety looks for this updated data cut? Previously, I think there were a couple of grade I don't know how many grade 5 events, so maybe walk us through. Are you seeing more grade five events?

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

We haven't provided a breakdown of this specifically, but I would say overall, there's clearly a reduction in the TRAEs grade four, five events, and overall, the safety profile beyond that is improved as well.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thank you.

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

And just to add one thing on that. After we had our hold by the FDA, obviously, we're under a microscope, yet you've seen we've not had a hold after multiple years. That should be indicative of the preserved safety that we were looking for.

Andrew Tsai
Senior Biotech Analyst, Jefferies

That makes sense. So, looking ahead, walk us through the cadence of events to get this approved ultimately.

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Yeah, I guess I'll just take that one too. So, we are imminently finishing this trial with 80 patients. We know 80 patients is the typical amount. We know that from our own experience with our first approval. We know that from multiple recent FDA approvals in the non-small cell lung cancer space. The next cadence, since we've already provided, as we said, we wanted a large corpus of data by the end of the year. We will have, at a major medical meeting, a fuller data set. We expect to submit an sBLA next year, then you'll hear more after that.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Major medical is like ASCO?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Something along those lines. That's right. It really depends on data cuts and their because they have their deadlines too, and everything has to align, of course.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Very clear. As that's going, you've decided to move forward with the POSITILITY trial. It's a pivotal trial looking at a subgroup of the wild-type KRAS, wild-type HER2, a smoking population. That's where you saw the larger 60% ORR in this updated data cut. Is this meant to kind of expand the label ultimately? Because it sounds like you're filing for second- line broad in the meantime. How does this benefit your label ultimately?

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

We want to be clear that we're filing for the broad population, and that's an event that will happen in 2027. In addition, we saw these remarkable results for the patients that have the, on top of the EGFR wild-type, ALK, and ROS non-mutated. Now we look at KRAS wild-type, HER2 wild-type ever smokers. We see this subpopulation, about 45% of the overall population, is achieving an excess of a 50% response rate, which is quite remarkable, with obviously long durations of responses. This we view as a subsequent filing that we'll do. When the POSITILITY cohort is done, it will happen while we're in the process of filing already for the broad population. We expect to go in with hopefully even better benefit-risk for a subset of patients, but consider it a subsequent filing.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thank you. In addition to that, I think POSITILITY is second- line, and now you have OPTILISM, which is first- line lung. That's also going in this biomarker-enriched population. That will start in 2027, but my question is, for both of these, POSITILITY, OPTILISM, when could we get data? It sounds as if we could get data as you're potentially getting approved in broad lung.

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

We haven't guided to when we'll provide data on it. OPTILISM will start in 2027. The POSITILITY cohort, let's keep in mind, we have IOV-LUN-202 202 study open. There are already sites that have been enrolling, so it's just a matter now of adding patients in this fifth cohort. That will be ongoing throughout the year. OPTILISM is a new study in its entirety, so we'll offer more guidance over the course of the year, but no timing on that yet.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, sounds good. Moving on, AMTAGVI now is also going after sarcomas, two rare sarcomas. There you have the SARATOGA study, and can you remind us how big it is? Is it a pivotal trial? When could we get data for that one?

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

SARATOGA is a trial that we're beginning now, and it will involve 80 patients, 40 patients each of two histologies that are seen within the soft tissue sarcoma population. That's UPS and DDLPS. These are the severest forms of soft tissue sarcomas. There really isn't treatment available for these patients that offers much at all. We recently provided data from a phase I study that illustrated, I'm sorry, an investigator-initiated trial that illustrated more than a 50% response rate with nice durability. We will expect over the course of the year updates on that study from the investigator, but in the meantime, we're going to be executing fearlessly on the SARATOGA study because there's so many patients in need. In terms of the patient size, I'll turn it to Dan.

Dan Kirby
Chief Commercial Officer, Iovance Biotherapeutics

Yeah, looking at this, the patient size is lower, but again, there's nothing else for those patients. So, the opportunity is the same as second- line plus melanoma. From the commercial side, I see the enrollment rates as we go in there. I can tell you, SARATOGA's off to a very fast start. That's extremely encouraging for me to see those patients going in there. We had a really productive ad board right before ASCO with the sarcoma thought leaders, and they were expressing their enthusiasm for this, and you can see that with how the trial's starting. So, we're very encouraged what we're seeing in the early days, and we do hope to have that data enrolled as quick as possible.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, great. Then 56% ORR, and then remind us what standard of care could get you on ORR?

Brian Gastman
EVP of Translational Medicine, Iovance Biotherapeutics

Yes, so maybe I'll take that. Basically, in the second- line, the major chemotherapies, which is really all that's out there, has around a 5% or less response rate. DOR is certainly less than six months. It's considered really palliation therapy in the second- line. To be truthful, the front line isn't that much better.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect. Okay, I think that's all the time we have. So, thank you so much for the updates.

Corleen Roche
CFO, Iovance Biotherapeutics

Thanks, Andrew.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Congrats on the progress.

Noah Berkowitz
Chief Medical Officer, Iovance Biotherapeutics

Thank you very much.